ReviewNature reviews. Gastroenterology & hepatology2010
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.
Review in Nature reviews. Gastroenterology & hepatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02765802 (A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection), which is not on this map. Cited by 130 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)
Who cites it
130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 395 citations in OpenAlex.
- Diagnostic Efficacy of Serological Antibody Detection Tests for Hepatitis Delta Virus: A Systematic Review and Meta-Analysis.Viruses · 2023Pooled it
- The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis.TheScientificWorldJournal · 2018Pooled it
- Interferon alpha for chronic hepatitis D.The Cochrane database of systematic reviews · 2011Pooled it
- Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.The Lancet. Infectious diseases · 2015Trial
- Absence of Detectable Anti-HDV Antibodies Among HBsAg-Positive Blood Donors, HIV-Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay.Journal of viral hepatitis · 2026Article
- Hepatitis D Virus: Enigmas and Gaps of Knowledge.Viruses · 2026Review
- Unexpectedly low prevalence of hepatitis delta virus infection in Southern Viet Nam.Scientific reports · 2025Article
- Unexpectedly Low Prevalence of Hepatitis Delta Virus Infection in Southern Viet Nam.Research square · 2025Article
- The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Article
- Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation Results From a French Multicentric Retrospective Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study.Journal of viral hepatitis · 2025Article
- A comprehensive review of diagnostic approaches for hepatitis D.Frontiers in molecular biosciences · 2025Review
- Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.Viruses · 2024Article
- Viral hepatitis-induced acute liver failure.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.JHEP reports : innovation in hepatology · 2024Article
- Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- Dynamics of Virological and Clinical Response Parameters of Bulevirtide Treatment for Hepatitis D: Real-World Data.Gastro hep advances · 2024Article
- Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States.Journal of viral hepatitis · 2023Article
- Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDV.JHEP reports : innovation in hepatology · 2023Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis D is caused by infection with the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans. Hepatitis D occurs only in individuals positive for the HBV surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. At least eight different HDV genotypes have been described and each has a characteristic geographic distribution and a distinct clinical course. HDV and HBV coinfection can be associated with complex and dynamic viral dominance patterns. Chronic HDV infection leads to more severe liver disease than HBV monoinfection and is associated with accelerated fibrosis progression, earlier hepatic decompensation and an increased risk for the development of hepatocellular carcinoma. So far, only IFN-alpha treatment has proven antiviral activity against HDV in humans and has been linked to improved long-term outcomes. Studies conducted in the past 2 years on the use of PEG-IFN-alpha show that a sustained virologic response to therapy, measured in terms of undetectable serum HDV RNA levels, can be achieved in about one quarter of patients with hepatitis D. Novel alternative treatment options including prenylation inhibitors are awaiting clinical development for use in hepatitis D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.